survivin Cancer Research Results

survivin, BIRC5: Click to Expand ⟱
Source:
Type: antiapoptosis protein
Survivin, BIRC5 (Baculoviral IAP Repeat Containing 5) is a potent anti-apoptosis protein that is differentially expressed in cancer and therefore constitutes an important anti-cancer target [49]. Moreover, high expression of survivin plays important role in resistance to chemo- and radiotherapy and has been shown to be related to unfavorable outcome for medulloblastomas.
"Survivin" is a protein that plays a crucial role in regulating cell division and inhibiting apoptosis (programmed cell death). It is part of the inhibitor of apoptosis (IAP) family and is often overexpressed in various types of cancer.
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
1142- Ash,    Ashwagandha-Induced Programmed Cell Death in the Treatment of Breast Cancer
- Review, BC, MCF7 - NA, BC, MDA-MB-231 - NA, Nor, HMEC
Apoptosis↑, ROS↑, DNAdam↑, OXPHOS↓, *ROS∅, Bcl-2↓, XIAP↓, survivin↓, DR5↑, IKKα↓, NF-kB↓, selectivity↑, *ROS∅, eff↓, Paraptosis↑,
6496- BCP,    β-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models
- vitro+vivo, CRC, HCT116 - in-vitro, Nor, HUVECs
angioG↓, VEGF↓, TumVol↓, Apoptosis↑, HSP60/HSPD1↓, HTRA↓, survivin↓, XIAP↓, P21↑, *toxicity↓, *neuroP↑, *ROS↓, *COX2↓, *Inflam↓, *cardioP↑, AntiCan↑, ChemoSen↑, ROS↑, MMP↑, Bax:Bcl2↑, TumCG↓,
7159- CHA,    ROS-mediated inactivation of the PI3K/AKT pathway is involved in the antigastric cancer effects of thioredoxin reductase-1 inhibitor chaetocin
- vitro+vivo, GC, HGC27 - in-vitro, GC, AGS - in-vitro, GC, BGC-823 - in-vitro, GC, SGC-7901 - in-vitro, Nor, HEK293
TumCP↓, TumCCA↑, Casp↑, Apoptosis↑, TrxR1↓, ROS↑, eff↓, eff↑, PI3K↓, Akt↓, TumCG↓, cl‑PARP↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, XIAP↓, survivin↓, TumVol↓, TumW↓, Weight∅, toxicity↓, Ki-67↓, other↝,
823- GAR,    Garcinol Potentiates TRAIL-Induced Apoptosis through Modulation of Death Receptors and Antiapoptotic Proteins
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF10 - in-vitro, CRC, HCT116
Casp3↑, Casp9↑, Casp8↑, DR5↑, survivin↓, Bcl-2↓, XIAP↓, cFLIP↓, BAX↑, Cyt‑c↑, ROS↑, GSH↓, *eff↓,
7245- Gink,    Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity
- vitro+vivo, Pca, DU145 - in-vitro, CRC, HCT116 - in-vitro, Nor, MCF10
STAT3↓, cycD1/CCND1↓, survivin↓, Bcl-2↓, Bcl-xL↓, TumCG↓, Dose↝, TumCCA↑, Apoptosis↑, TumVol↓, TumW↓,
6775- Neem,  Nimb,    Therapeutics Role of Azadirachta indica (Neem) and Their Active Constituents in Diseases Prevention and Treatment
- Review, Nor, NA
*antiOx↑, P53↑, PTEN↑, NF-kB↓, PI3K↓, Akt↓, Bcl-2↓, VEGF↓, *Inflam↓, *COX2↓, *5LO↝, *Wound Healing↑, *Imm↑, *hepatoP↑, *AntiDiabetic↑, *neuroP↑, *AntiViral↑, *Bacteria↑, *AntiBio↑, *AntiFungal↑, cMyc↓, BAX↓, IAP1↓, IAP2/BIRC3↓, Bcl-xL↓, survivin↓, XIAP↓, angioG↓,
5123- Sal,    Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells
- in-vitro, BC, MCF7 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, HEK293
Wnt↓, β-catenin/ZEB1↓, mTORC1↓, GSK‐3β↑, cycD1/CCND1↓, survivin↓, LRP6↓, TumCG↓, Apoptosis↑,

Showing Research Papers: 1 to 7 of 7

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

HSP60/HSPD1↓, 1,   HTRA↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 1,   OXPHOS↓, 1,   ROS↑, 4,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↑, 1,   XIAP↓, 5,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 5,   BAX↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 5,   Bcl-xL↓, 3,   Casp↑, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp8↑, 1,   cl‑Casp8↑, 1,   Casp9↑, 1,   cl‑Casp9↑, 1,   cFLIP↓, 1,   Cyt‑c↑, 1,   DR5↑, 2,   IAP1↓, 1,   IAP2/BIRC3↓, 1,   Mcl-1↓, 1,   Paraptosis↑, 1,   survivin↓, 7,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 2,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

GSK‐3β↑, 1,   LRP6↓, 1,   mTORC1↓, 1,   PI3K↓, 2,   PTEN↑, 1,   STAT3↓, 1,   TumCG↓, 4,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ki-67↓, 1,   TumCP↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2,   VEGF↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IKKα↓, 1,   NF-kB↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff↓, 2,   eff↑, 1,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↓, 1,   TumVol↓, 3,   TumW↓, 2,   Weight∅, 1,  
Total Targets: 64

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ROS↓, 1,   ROS∅, 2,  

Migration(tgid=13) ⓘ

5LO↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   Imm↑, 1,   Inflam↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiDiabetic↑, 1,   cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 2,   toxicity↓, 1,   Wound Healing↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   AntiViral↑, 1,   Bacteria↑, 1,  
Total Targets: 18

Scientific Paper Hit Count for: survivin, BIRC5
1 Ashwagandha(Withaferin A)
1 Beta-Caryophyllene
1 chaetocin
1 Garcinol
1 Ginkgetin
1 Neem
1 Nimbolide
1 salinomycin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:299  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page